^




    Show legend
    Group by Gene:
    Include preclinical:

    regorafenib
    pazopanib
    ponatinib
    		0
    Multi-tyrosine kinase inhibitor
    cabozantinib tablet
    anlotinib
    MGCD516
    vandetanib
    1
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    pembrolizumab + ipilimumab
    temozolomide
    gemcitabine
    		2
    DNA synthesis inhibitor
    dacarbazine
    gemcitabine + dacarbazine
    cisplatin
    nivolumab
    		3
    PD1 inhibitor
    pembrolizumab
    camrelizumab
    PDR001
    crizotinib
    		4
    ALK inhibitor
    ceritinib
    alectinib
    everolimus
    		5
    mTOR inhibitor
    temsirolimus
    sirolimus
    doxorubicin hydrochloride
    		6
    Topoisomerase II inhibitor
    epirubicin
    pegylated liposomal doxorubicin
    7
    Progesterone receptor agonist
    megestrol
    8
    Topoisomerase I inhibitor
    topotecan
    irinotecan
    9
    Alkylating agent, DNA inhibitor
    trabectedin
    PARP inhibitor
    		10
    PARP inhibitor
    olaparib
    rucaparib
    11
    EZH2 inhibitor
    tazemetostat
    SHR-2554
    12
    Bcr-abl tyrosine kinase inhibitor
    nilotinib
    olverembatinib
    atezolizumab
    		13
    PD-L1 inhibitor
    envafolimab
    STI-A1014
    14
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    abemaciclib
    15
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    doxorubicin hydrochloride + ifosfamide
    ifosfamide + epirubicin
    		16
    Bifunctional alkylating agent, Topoisomerase II inhibitor
    ifosfamide + pegylated liposomal doxorubicin
    doxorubicin hydrochloride + ifosfamide
    ifosfamide + epirubicin
    17
    XPO1 inhibitor
    selinexor
    18
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    temozolomide + irinotecan
    19
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    20
    Bifunctional alkylating agent
    ifosfamide
    21
    VEGFR inhibitor, PD1 inhibitor
    pembrolizumab + axitinib
    sintilimab + fruquintinib
    22
    VEGF-A inhibitor
    bevacizumab
    23
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    vincristine
    24
    Proteasome inhibitor
    bortezomib
    25
    Selective estrogen receptor degrader
    fulvestrant
    26
    Tubulin polymerization inhibitor, DNA synthesis inhibitor
    gemcitabine + vinorelbine tartrate
    27
    PDGFR α antagonist
    olaratumab
    28
    EGFR inhibitor
    erlotinib
    29
    VEGFR inhibitor
    cediranib
    30
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    31
    Alkylating agent
    melphalan + busulfan
    cyclophosphamide
    32
    Topoisomerase II inhibitor, RNA synthesis inhibitor
    dactinomycin
    33
    Tubulin polymerization promoter, Alkylating agent
    carboplatin + cyclophosphamide
    34
    Bifunctional alkylating agent, Tubulin polymerization promoter
    carboplatin + ifosfamide
    35
    Mitosis inhibitor
    vinorelbine
    36
    Alkylating agent, Tubulin polymerization inhibitor
    cyclophosphamide + vinorelbine tartrate
    37
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor, Tubulin inhibitor
    methotrexate + vinblastine
    38
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization inhibitor
    doxorubicin hydrochloride + ifosfamide + vincristine
    39
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    40
    TNF inhibitor
    thalidomide
    RAIN-32
    		41
    MDM2 inhibitor
    APG-115
    MK-8242
    HDM201
    42
    LSD1 inhibitor
    SP2577
    43
    HSP90 inhibitor
    pimitespib
    IPI 493
    44
    Aromatase inhibitor
    Aromatase inhibitor
    anastrozole
    45
    MEK inhibitor
    binimetinib
    trametinib
    46
    TCR modulator, MAGE-A4 inhibitor
    ADP-A2M4
    47
    mTORC1 inhibitor
    nanoparticle albumin-bound rapamycin
    48
    DNA topoisomerase inhibitor, Topoisomerase II-alpha inhibitor, Topoisomerase II-beta inhibitor
    L-ANN
    49
    BMI1 inhibitor
    BMIi-1
    50
    TRAIL R2 agonist
    INBRX-109
    AMG 655
    selpercatinib
    		51
    RET inhibitor
    pralsetinib
    TAS0953 / HM06
    52
    TCR modulator, NY ESO 1 inhibitor
    TAEST16001
    TBI-1301
    53
    PD-L1 inhibitor, PARP inhibitor
    avelumab + talazoparib
    54
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    55
    MDM2-p53 antagonist
    BI 907828
    56
    Macrophage stimulant, Monocyte stimulant
    mifamurtide
    57
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    58
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + toripalimab-tpzi
    IGF-1R inhibitor
    		59
    IGF-1R inhibitor
    CP-751,871
    ASP7487
    60
    PTPN11 inhibitor
    RMC-4630
    61
    Hedgehog cell-signalling pathway inhibitor
    vismodegib
    62
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    63
    CD70-targeted antibody-drug conjugate
    ARX305
    64
    GD2 ganglioside inhibitor
    dinutuximab beta
    65
    MEK inhibitor, Multi-tyrosine kinase inhibitor
    trametinib + pazopanib
    66
    IDH1 inhibitor
    ivosidenib
    67
    PRMT5 inhibitor
    MRTX1719
    68
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    69
    Glutaminase inhibitor
    IPN60090
    70
    AKT inhibitor
    capivasertib
    71
    AMPK activator
    metformin
    72
    HER2 inhibitor, γδ TCR modulator
    Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
    73
    DNA synthesis inhibitor, PARP inhibitor
    olaparib + temozolomide
    ICE
    OPEC
    MAID
    VDC
    VAIA
    VIDE
    		74
    Chemotherapy
    MAP
    AD
    AIM
    IE
    VC
    GT
    VAC
    FAC
    75
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    76
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    77
    mTOR inhibitor, IGF-1R inhibitor
    mTOR inhibitor + IGF-1R inhibitor
    78
    ATR inhibitor, PARP1 inhibitor
    ATR inhibitor + PARP1 inhibitor
    79
    Immunotherapy
    Immunotherapy
    80
    c-MET inhibitor, MEK inhibitor
    MEK inhibitor + c-MET inhibitor
    81
    CDK12 inhibitor
    CDK12 inhibitor
    82
    PDGFR inhibitor, HDAC inhibitor
    PDGFR inhibitor + HDAC inhibitor
    83
    PDGFR inhibitor
    PDGFR inhibitor
    84
    GnRH agonist
    GnRH agonist
    85
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    86
    PDGFR α inhibitor, c-KIT inhibitor, FLT3 inhibitor
    ripretinib
    87
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    88
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    sunitinib + PLX9486
    89
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    90
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    91
    THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor
    cisplatin + doxorubicin hydrochloride + methotrexate
    92
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    93
    Alkylating agent, Topoisomerase I inhibitor
    cyclophosphamide + topotecan
    94
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + ifosfamide + etoposide IV
    95
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, RNA synthesis inhibitor
    vincristine + dactinomycin
    96
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA inhibitor
    carboplatin + etoposide oral
    97
    THF dehydrogenase inhibitor, Tubulin polymerization inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate + vinorelbine tartrate
    98
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Alkylating agent, Tubulin polymerization inhibitor
    doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
    99
    Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA inhibitor, Dihydrofolic acid reductase inhibitor
    ifosfamide + methotrexate + etoposide oral
    100
    Tubulin polymerization inhibitor, Topoisomerase I inhibitor
    irinotecan + vincristine
    101
    Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor
    cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate
    102
    Bifunctional alkylating agent, Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    gemcitabine + docetaxel + ifosfamide
    103
    Topoisomerase II inhibitor, Alkylating agent
    cyclophosphamide + etoposide IV
    104
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    105
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + ifosfamide + pegylated liposomal doxorubicin
    cisplatin + ifosfamide + epirubicin
    106
    Topoisomerase II inhibitor, Tubulin polymerization promoter, Alkylating agent
    carboplatin + cyclophosphamide + etoposide IV
    107
    Tubulin polymerization inhibitor, DNA synthesis inhibitor, Topoisomerase I inhibitor
    temozolomide + irinotecan + vincristine
    108
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    doxorubicin hydrochloride + dacarbazine
    cisplatin + doxorubicin hydrochloride
    109
    TNFα inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
    pomalidomide
    110
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    gemcitabine + docetaxel
    111
    Microtubule stabilizer, Tubulin polymerization promoter, Alkylating agent, DNA synthesis inhibitor
    gemcitabine + docetaxel + cyclophosphamide
    112
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    113
    Topoisomerase II inhibitor, Alkylating agent, Tubulin polymerization inhibitor
    doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
    114
    Bifunctional alkylating agent, Topoisomerase II inhibitor, Alkylating agent, Topoisomerase I inhibitor
    cyclophosphamide + ifosfamide + etoposide IV + topotecan
    115
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    116
    RNA polymerase inhibitor, Alkylating agent, Apoptosis stimulant
    lurbinectedin
    117
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    118
    ALK inhibitor, EGFR inhibitor
    brigatinib
    119
    pan-RAF inhibitor, mTOR inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + everolimus
    120
    PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
    avapritinib
    121
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    122
    EWS-FLI1 inhibitor, ETS inhibitor
    ONCT-216
    123
    Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor
    doxorubicin hydrochloride + trabectedin
    124
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + pemetrexed
    125
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    126
    GPR20 -targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DS-6157
    127
    pan-RAF inhibitor, VEGF-A inhibitor, mTOR inhibitor, Multi-tyrosine kinase inhibitor
    bevacizumab + sorafenib + temsirolimus
    128
    Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, DNA intercalator
    cytarabine + daunorubicin
    129
    PDGFR β inhibitor, PDGFR α inhibitor, FLT3 inhibitor
    ARO-002
    130
    PD1 inhibitor, GM-CSF agonist
    nivolumab + talimogene laherparepvec
    131
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, CDK4 inhibitor, CDK6 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    palbociclib + lenvatinib
    132
    VEGFR inhibitor, PDGFR inhibitor, PD1 inhibitor, c-KIT inhibitor
    nivolumab + sunitinib
    133
    pan-RAF inhibitor, Src kinase inhibitor
    BAL3833
    134
    PD1 inhibitor, CD122 agonist, IL-2 stimulant
    nivolumab + NKTR-214
    135
    MCL1 inhibitor, Bcl2 inhibitor
    venetoclax + S63845
    136
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, mTOR inhibitor, c-KIT inhibitor
    imatinib + everolimus
    137
    FGFR4 inhibitor
    ABSK012
    138
    Trk inhibitor
    BAY 2731954
    139
    c-KIT-targeted antibody-drug conjugate, Microtubule inhibitor
    LOP628
    140
    WEE1 inhibitor
    AZD1775
    141
    PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor, WEE1 inhibitor
    AZD1775 + avapritinib
    142
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    143
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    144
    CD122 agonist, IL-2 stimulant
    NKTR-214
    145
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor, MDM2 inhibitor
    erdafitinib + RG7388
    146
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    147
    PLK4 inhibitor
    CFI-400945
    148
    HDAC inhibitor
    vorinostat
    romidepsin
    149
    MCSP inhibitor
    CSPG4.TNK
    150
    Ionizing radiation emitter, FAP inhibitor
    AAA614
    151
    VEGFR inhibitor, HSP90 inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib + IPI 493
    152
    Tubulin binding agent, Microtubule inhibitor
    PM184
    153
    FGFR inhibitor, PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib + infigratinib
    154
    CD30-targeted antibody-drug conjugate, ALK inhibitor, Microtubule inhibitor
    ceritinib + brentuximab vedotin
    crizotinib + brentuximab vedotin
    155
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor
    brentuximab vedotin
    156
    β-catenin inhibitor, Microtubule stabilizer, Tubulin polymerization promoter, CBP inhibitor, Microtubule inhibitor
    docetaxel + eribulin mesylate
    157
    Glutamine antagonist, Nerve growth factor inhibitor
    DR6MP + JHU395
    158
    Nerve growth factor inhibitor
    DR6MP
    159
    IDH2 inhibitor
    enasidenib
    160
    CSF-1R inhibitor
    ABSK021
    161
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    entinostat
    162
    CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor
    DSP-2033
    163
    β-catenin inhibitor, XPO1 inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate + selinexor
    164
    Bifunctional alkylating agent, Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel + ifosfamide
    165
    Bcl2 inhibitor
    venetoclax
    166
    Reactive oxygen species stimulant, Photosensitizer
    verteporfin
    167
    Proteasome inhibitor, CDK9 inhibitor, P-TEFb inhibitor
    carfilzomib + VIP152
    bortezomib + VIP152
    168
    c-KIT inhibitor
    IDRX-42
    169
    ATR inhibitor
    BAY 1895344
    170
    CXCL12 inhibitor, Farnesyl transferase inhibitor, MEK inhibitor
    trametinib + tipifarnib
    171
    MEK inhibitor, IGF-1R inhibitor
    trametinib + AMG 479
    172
    XPO1 inhibitor, CDK9 inhibitor, P-TEFb inhibitor
    selinexor + VIP152
    173
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PD1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    PD1 inhibitor + chidamide
    174
    CDK9 inhibitor, P-TEFb inhibitor
    VIP152
    No biomarker
    ALK translocation
    ALK rearrangement
    ALK fusion
    KIT mutation
    KIT exon 13 mutation
    KIT exon 17 mutation
    KIT exon 11 mutation
    KIT exon 18 mutation
    KIT exon 14 mutation
    KIT expression
    KIT W557_V559>C
    KIT exon 17 mutation + KIT exon 18 mutation
    KIT W557_V559>F
    KIT V654A
    KIT Y823D
    KIT N822Y
    KIT D820A
    KIT D820G
    KIT N822K
    KIT D820Y
    KIT M552_V555delMYEV
    KIT wild-type
    KIT positive
    KIT V559_E561del
    KIT exon 11 mutation + KIT exon 17 mutation
    KIT V560E
    KIT N820Y
    KIT exon 9 mutation
    KIT P577del + KIT W557Lfs*5 + KIT Y823D
    KIT exon 11 W557_K558delins
    KIT W557_V559delinsF
    KIT D818Y
    TMB-H
    SDHB deletion
    SDHB mutation
    PGR positive
    HR positive
    ER positive + PGR positive
    ER positive
    EGFR expression
    EGFR overexpression
    CALB1 deletion
    CALB1 underexpression
    PDGFRA D842V
    PDGFRA exon 18 mutation
    PDGFRA mutation
    PDGFRA I843_D846delIMHD
    PDGFRA overexpression
    PDGFRA underexpression
    SMARCB1 deletion
    SMARCB1 A240fsX28
    SMARCB1 mutation
    SMARCB1 negative
    PD-L1 expression
    PD-L1 overexpression
    PIK3CA E542K
    PIK3CA mutation
    PIK3CA amplification
    TMB-H + PD-L1 expression
    PIK3CA M1043I
    MDM2 amplification
    GRM1 overexpression
    TP53 wild-type
    CDK4 amplification
    NTRK3 fusion
    BRAF V600E
    BRAF V600
    TP53 mutation
    NF1 mutation
    CDK4 overexpression
    NF1 mutation
    NTRK3 translocation
    NF1 rearrangement
    MDM2 overexpression
    TP53 overexpression
    MSI-H/dMMR
    RET fusion
    IDH1 mutation
    ERCC1 overexpression
    PTPRD R995C
    TFG-ROS1 rearrangement
    PGP expression
    KRAS G12V
    TFG-ROS1 fusion
    HER-2 negative
    PD-1 overexpression
    FIP1L1-PDGFRA fusion
    HER-2 positive
    ERCC1 underexpression
    PGP overexpression
    KRAS Q61H
    HLA-A*02:01 + MAGEA4 expression
    PTPRD V253I + PTPRD W775stop
    KDR amplification
    PD-1 expression
    HLA-A*02 + MAGEA4 expression
    KDR overexpression
    FIP1L1-PDGFRA rearrangement
    HER-2 expression
    ERCC1 K504Q
    ERCC1 N118N
    BRCA2 mutation
    NTRK2 fusion
    NTRK1 fusion
    MAGEA4 expression
    TFE3 fusion
    MGMT promoter methylation
    HLA-A*02:01
    CTAG1B expression
    CREB3L1 expression
    CUL4A overexpression
    ERCC5 overexpression
    KIAA1549-BRAF fusion
    IGF1R underexpression
    EWSR1-NR4A3 fusion
    AKT1 E17K
    CBL mutation
    IGF1 elevation
    SS18-SSX fusion
    IFIH1 expression
    CTSG expression
    XPC K939G
    STC2 expression
    SECTM1 expression
    LAG3 overexpression
    CTLA4 overexpression
    RB1 expression
    CD70 expression
    SDHC mutation
    TMEM127 mutation
    SRC mutation
    APC mutation
    TFE3 rearrangement + MET expression
    IDH2 mutation
    HDAC1 amplification
    DEPDC5 deletion
    CLDN6 positive
    SPARC overexpression
    MET amplification
    TAF15-CHN1 translocation
    FUS-DDIT3 translocation
    AKT1 mutation + mTOR mutation
    TPM4-NTRK3 fusion
    MAD2L2 underexpression
    XRCC2 underexpression
    RAD54L underexpression
    BLM underexpression
    APEX2 underexpression
    ATM overexpression
    SLFN11 overexpression
    PIK3R1 overexpression
    CDKN2A overexpression
    MCM4 overexpression
    COL1A1-PDGFB fusion
    KANK1-NTRK2 fusion
    ERC1-ALK fusion
    TYMS underexpression
    ALDH1A1 rs3764435
    B4GALNT1 expression
    PALB2 deletion
    PDGFRB overexpression
    EZH2 underexpression
    RAD51B deletion
    KIT wild-type + SDHB deletion
    KDR overexpression + PDGFRB overexpression
    PTCH E947T
    HRD
    BRCA1 mutation
    MDM2 amplification + TP53 wild-type
    MDM2 amplification + TWIST1 amplification
    EWSR1-FLI1 fusion
    MDM2 amplification + TP53 wild-type + TWIST1 amplification
    HLA-A*02:01 + CTAG1B expression
    TNFRSF14 overexpression
    DUSP9 underexpression
    TERT mutation
    PIK3CA wild-type + PTEN wild-type
    LMNA-NTRK1 fusion
    ATF1 overexpression
    YWHAE-ROS1 fusion
    RBPMS-MET fusion
    CARS1‐ALK fusion
    TPM3-NTRK1 fusion
    FLT4 amplification
    JAK1 overexpression
    KIAA1549-BRAF fusion + PTEN deletion
    STRN-NTRK2 fusion + CDKN2B Deletion
    KDR Q472H + KIT M541L
    TMB-H + PD-L1 overexpression
    NTRK1-KHDRBS1 fusion
    EML4-ALK + ALK-PEX13
    MYH9-ALK + ALK-WDR43
    RANBP2-ALK + TMEM217-ALK
    PTEN mutation + TSC1 mutation
    AFP elevation + VIM positive
    FN1-ALK fusion
    YWHAE-JAZF1 fusion
    NR4A3 rearrangement + KIT mutation
    KRAS G12D + DNMT3A C559fsX
    SMARCA4 deletion
    QKI-RAF1 fusion
    KIT positive + CD34 positive + ANO1 positive + ACTA2 positive
    CD99 positive + VIM positive
    NUTM1-MXI1 rearrangement
    SDHB mutation + NF1 mutation
    ASPSCR1-TFE3 fusion +TMB-H
    EWSR1 rearrangement
    TRIM33-RET fusion
    DICER1 A1690Gfs*9 + DICER1 E1813Q + KRAS G12L
    NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion
    EML4-NTRK3 rearrangement
    EWSR1-CREM fusion
    STRN-NTRK2 fusion
    IGF1R expression
    CDKN2A deletion
    BRCA2 deletion
    IDH2 R172G
    RB1 positive
    PDGFRB underexpression
    DDR
    Chr del(2)(p12)
    IL7R-BCL2 fusion
    HRAS mutation
    RAS mutation
    EWSR1-TFCP2 fusion
    BCL2 underexpression
    MYCN amplification
    TSC2 A736V
    MCL1 amplification
    CSF1R overexpression
    NF2 E108X
    PDZK1IP1 overexpression
    ABCG2 overexpression
    HMGA1 overexpression
    SUFU mutation
    AXL underexpression
    STK33 underexpression
    PTEN deletion
    CD8 positive
    GPR20 expression
    TEKT4 mutation
    FGFR1 overexpression
    FGFR4 overexpression
    PLK4 expression
    FGFR4 V550L
    RAD23B overexpression
    FUS-ERG fusion
    PAK4 deletion
    CSPG4 overexpression
    HAT1 overexpression
    FAP expression
    ERCC2 D312N
    ERCC2 K751G
    ATRX mutation
    Chr amplification(4)(q26)
    Chr amplification(20)(p12.2)
    FGF2 elevation
    CASP8 overexpression
    RANBP2-ALK rearrangement + TNFRSF8 expression
    Chr amplification(13)(q13.3)
    Chr amplification(8)(q22.2)
    Chr amplification(8)(q13.2)
    EWSR1-WT1 fusion
    MAN1A1-ROS1 rearrangement
    CYP3A4 overexpression
    PDE4DIP-NTRK1 fusion
    CYP3A5 underexpression
    ETV6-NTRK3 fusion
    SQSTM1-NTRK1 fusion
    KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128
    Chr del(1)(q44)
    FGFR3 amplification + FGFR4 amplification + FLT4 amplification
    KDM1A overexpression
    DCTN1-NTRK1 fusion
    MALAT1 overexpression
    BRAF-MAD1L1 fusion
    MDM2 amplification + CDK4 amplification
    PAX3-FOXO1 fusion
    Chr del(2)(q14.1)
    MSH3 overexpression
    PARP1 underexpression
    Chr del(11)(q25)
    PBRM1 mutation
    RANBP2-ALK fusion
    TJP1-ROS1 fusion + NF1 mutation
    ABCG2 expression
    ABCB1 expression
    MVP expression
    ALK1 rearrangement
    ABCC1 expression
    PIK3CA mutation + TERT promoter mutation
    Chr del(3)(q14.2)
    TP53 deletion + RB1 deletion + CTSK expression
    Chr amplification(4)(q22.1)
    PML-JAK1 fusion
    SPECC1L-RET fusion
    TAF15-NR4A3 fusion